Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,061,880 papers from all fields of science
Search
Sign In
Create Free Account
liarozole
An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Broader (5)
Androgen Antagonists
Antineoplastic Agents, Hormonal
Dermatologic Agents
Enzyme Inhibitors
Expand
Liarozole Hydrochloride
NCIt Antineoplastic Agent Terminology
liarozole fumarate
Narrower (3)
Liazal
R 085246
R 75251
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Preclinical evaluation of vitamin D and ginsenoside metabolites in combination for prostate cancer therapy : pharmacokinetic and pharmacodynamic interactions
M. Ben-Eltriki
2018
Corpus ID: 57929856
........................................................................................................................... iii…
Expand
2017
2017
Inhibition of CYP 2 S 1 mediated metabolism of anticancer prodrug AQ 4 N by liarozole
Naveen K Singh
,
Shawn R. White
,
S. Kalagara
,
Samuel Kadavakollu
2017
Corpus ID: 115137783
Article history: Received on: 21/04/2016 Accepted on: 30/06/2016 Available online: 27/02/2017 CYP2S1 is an orphan Cytochrome P450…
Expand
2008
2008
Design, synthesis and binding studies of novel CYP26 inhibitors
S. Pautus
2008
Corpus ID: 82832022
All-frans-retinoic acid ATRA has shown spectacular success in the treatment of cancer and leukaemia, however ATRA is rapidly…
Expand
2008
2008
Retinoic Acid Metabolism Blocking Agents and the Skin : In vivo and in vitro Studies of the Effects on Normal and Diseased Human Epidermis
E. P. Lorié
2008
Corpus ID: 82238351
The biosynthesis of retinoic acid (RA) from retinol is controlled by several enzymes, e.g. dehydrogenases (RalDH2, RoDH-4) and…
Expand
2000
2000
Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention?
R. Lotan
Clinical Cancer Research
2000
Corpus ID: 5607777
In this issue of Clinical Cancer Research , Zeng et al. [(1)][1] describe the analysis of putative intermediate biomarker gene…
Expand
1998
1998
Original Paper Early Clinical Experience with Liarozole (Liazal 2 ) in Patients with Progressive Prostate Cancer
L. Denis
,
F. Debruyne
,
P. Porre
,
J. Bruynseels
1998
Corpus ID: 79716797
Liarozole (Liazal 2 ) is the first retinoic acid (RA) metabolism blocking agent (RAMBA) in clinical practice. RAMBA therapy…
Expand
1996
1996
Liarozole: A Viewpoint
C. Mahler
1996
Corpus ID: 72910112
1995
1995
Neue Antipsoriatika leuchten am Horizont
P. Kerkhof
,
M. Gerritsen
,
R. J. V. Dooren-Greebe
,
E. D. Jong
,
L. Ueberhorst
1995
Corpus ID: 68559924
New antisporiatic treatments and developments of existing treatments provide new perspectives for patients with psoriasis. Short…
Expand
1993
1993
Oral Liarozole as a Catabolic Inhibitor Potently Increases Retinoic Acid in vivo: First Experience from an Ongoing Therapeutic Trial in Highly Malignant Primary Brain Tumors
M. Westarp
,
M. P. Westarp
,
J. Bruynseels
,
W. Bollag
,
H. Kornhuber
1993
Corpus ID: 70828589
Background: Retinoic acid, the intracellular metabolite of vitamin A, induces differentiation in glioblastoma cultures and…
Expand
1993
1993
Liarozole: a new type of systemic antipsoriatic?
G. Higgins
1993
Corpus ID: 72660818
Liarozole [Johnson & Johnson], an analogue of the antifungal ketoconazole, has been chosen for development as a systemic…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE